
Left Atrial Appendage (LAA) Closure is a specialized procedure designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In AFib, the heart's upper chambers beat irregularly, which can cause blood to pool and form clots in a small, thumb-sized pouch called the left atrial appendage. This procedure serves as a primary alternative for patients who cannot tolerate long-term blood thinners.
Stroke Risk: Increased risk of stroke specifically due to non-valvular atrial fibrillation.
Bleeding History: A history of serious gastrointestinal bleeding or other major bleeding events that make anticoagulants dangerous.
Lifestyle Risks: A high risk of falls or an occupation/lifestyle that carries a significant risk of physical injury.
Medication Challenges: Difficulty maintaining therapeutic blood-clotting levels (INR) on traditional medications.
Long-term Preference: Preference for a one-time procedural solution over the requirement for lifelong daily anticoagulants.
Transcatheter LAA Closure: A minimally invasive method using a catheter inserted through the groin to "plug" the appendage.
Watchman Device Implantation: The use of a permanent, parachute-shaped device to seal the opening of the LAA.
Amulet Occluder: A specialized dual-seal device designed to provide complete and secure closure of the pouch.
Tissue Overgrowth: A natural biological process where heart tissue covers the device surface over approximately 45 days.
Device Occlusion: Deployment of low-profile devices to block the opening and prevent clots from escaping into the bloodstream.
Catheter Access: A small incision is made in the groin (femoral vein), and a thin tube is guided up to the heart.
Transseptal Puncture: The cardiologist carefully passes the catheter from the right atrium to the left atrium to reach the appendage.
Device Navigation: Under real-time imaging guidance, the permanent plug is guided precisely into the opening of the LAA.
Permanent Sealing: The device acts as a physical barrier; within weeks, heart tissue grows over it to create a permanent seal.
Positioning Verification: Real-time imaging (TEE) ensures the device is perfectly positioned and there are no leaks before the procedure is completed.
Fasting (NPO): No food or drink for 8–12 hours before the scheduled catheterization.
Baseline Diagnostics: Blood tests, ECG, and chest X-rays to assess overall cardiac health and kidney function.
Medication Adjustment: Adjusting current blood-thinning medications as directed by the electrophysiology team.
Allergy Discussion: Discussing any known allergies, particularly to nickel or the contrast dye used during imaging.
Recovery Logistics: Arranging for an overnight hospital stay and a support person to assist during the initial recovery period.
Transesophageal Echocardiogram (TEE): An ultrasound through the esophagus to check for existing clots and measure the appendage size.
Cardiac Catheterization: To evaluate heart pressures and map the specific atrial anatomy.
Cardiac CT Scan: For detailed 3D mapping of the appendage shape to select the correct device size.
ECG: To monitor the heart's electrical rhythm and confirm the current status of the atrial fibrillation.
Pulse Oximetry: To evaluate baseline oxygen saturation levels in the blood.
Observation Stay: A short hospital stay, typically requiring only one night for observation of the access site.
Short-term Medication: Patients usually remain on blood thinners and aspirin for the first 45 days until the heart tissue has healed over the device.
Medication Cessation: Most patients can eventually stop taking potent blood thinners once the seal is confirmed by follow-up imaging.
Activity Restrictions: Avoid strenuous activity or heavy lifting for approximately one week post-procedure to allow the groin incision to heal.
Ongoing Monitoring: Regular follow-up visits with a cardiologist to monitor the device and overall heart health.
Stroke Protection: Provides stroke protection comparable to warfarin while significantly reducing the risk of major bleeding.
Injury Safety: Restores peace of mind for patients who are at high risk of injury, bruising, or falls.
Success Rates: Features high technical success rates, with successful device placement often exceeding 95%.
Embolism Prevention: Effectively protects the brain from potential clots escaping the heart's upper chambers.
Therapy Elimination: Provides a long-term solution that eliminates the need for lifelong anticoagulant (blood thinner) therapy.